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However, each e-tongue sensor demonstrated different sensitivity 
suggesting a careful consideration of the experimental findings during melt 
extrusion is necessary for the development of taste masked formulations. 
Furthermore, FT-IR spectroscopy and NMR studies revealed possible drug 
polymer intermolecular interactions as the mechanism of successful taste 
masking.  
Conclusions HME can effectively be used to manufacture taste masked 
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Abstract 1 
 2 
Objectives The efficiency of the Astree e-tongue and Taste Sensing system TS5000Z for the 3 
evaluation of the taste masking effect of hot melt extruded formulations was investigated in 4 
this study.  5 
Methods Hot melt extrusion (HME) processing was optimized using Randcastle single screw 6 
extruder (USA) to manufacture extrudates with desirable characteristics. Cationic model drug 7 
propranolol HCl (PRP) was processed with the anionic polymers - Eudragit L100® (L100) 8 
and Eudragit L100-55 (Acryl-EZE). Solid state of the drug in polymer matrices was 9 
evaluated by scanning electron microscopy (SEM), differential scanning calorimetry (DSC), 10 
particle size analysis, Fourier Transform Infra-Red (FT-IR) and Nuclear Magnetic Resonance 11 
(NMR) analysis. In vitro taste masking efficiency of the two polymers was performed by 12 
using two different e-tongues (Astree e-tonge and TS5000Z). The results obtained from both 13 
e-tongues were further compared and contrast to find out the sensor outputs in all 14 
formulations. 15 
Key Findings Solid state analysis of the extruded formulations revealed the presence of 16 
amorphous PRP. Both e–tongues were able to detect the taste masking variations of the 17 
extrudates and were in good agreement with the in vivo results obtained from a panel of six 18 
healthy human volunteers (R
2
>0.84). However, each e-tongue sensor demonstrated different 19 
sensitivity suggesting a careful consideration of the experimental findings during melt 20 
extrusion is necessary for the development of taste masked formulations. Furthermore, FT-IR 21 
spectroscopy and NMR studies revealed possible drug polymer intermolecular interactions as 22 
the mechanism of successful taste masking.  23 
Conclusions HME can effectively be used to manufacture taste masked extruded 24 
formulations while both e-tongues demonstrated satisfactory taste analysis for the 25 
development of taste masked formulations. 26 
Keywords: Taste masking, Propranolol HCl®, Eudragit L100®, Acryl-EZE, Astree E-27 
Tongue, TS5000Z. 28 
  29 
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Introduction 30 
Masking the bitter taste of active pharmaceutical ingredients (APIs) is considered a major 31 
challenge especially for the development of orally administered dosage forms in 32 
pharmaceutical industry. 
[1, 2] 
Due to the unpleasant sensation bitter taste is always the least 33 
desired and sometimes completely undesired option whereas sweet taste is pleasant for most 34 
of the people regardless their age and origin. 
[3] 
In reality most of the APIs used in oral drug 35 
products have a bitter taste which is not only undesirable but also frequently has a negative 36 
influence on the palatability of the final dosage forms. For paediatric population 37 
unpalatable/bitter taste is the most challenging as children are highly sensitive to taste and 38 
actively refuse the unpalatable drugs. 
[4, 5]
 It is often impossible to block bitter taste receptors 39 
(due to their increased numbers) from the drug without compromising the mechanism of its 40 
action. 
[6, 7]
 The extent of taste masking of an API depends almost exclusively on the type of 41 
formulation (solid or liquid). Being the first preference, commercial oral liquid dosage forms 42 
contain artificial sweeteners (e.g saccharin and aspartame) and flavours to mask the tastes 43 
which are often limited due to the regulatory requirements. Due to very poor effects of this 44 
method and possibilities of toxic and allergic reactions, European Medicines Agency (EMA) 45 
strongly recommends another way for taste masking instead of adding sweeteners or flavours. 46 
[8]
 An ideal solution for this problem should involve the prevention of any contact of the 47 
unpalatable APIs with the taste buds without the addition of taste additives. Such an ideal 48 
formulation can be developed by applying an appropriate coating or encapsulation on the API 49 
or via manufacturing solid dispersions 
[9, 10]
 in inert matrices (polymeric/ lipidic). The coated/ 50 
encapsulated drug then can be dispersed in water.   51 
In vivo taste masking evaluation studies are performed by healthy human volunteers 52 
and involve taste assessments based on the individual scores. 
[11] 
A well-established statistical 53 
method is required to overcome errors and variability between volunteers within the limit of 54 
threshold taste perceptions. According to the FDA guidelines studies on paediatric 55 
formulations should not be performed on paediatric volunteers due to ethical conflicts. On the 56 
other hand in order to design paediatric formulations mature volunteers should also be 57 
prohibited due to large physiological differences of taste sensation. 
[7]
 Ethical doubts on 58 
experiments in children and difficulties with interpretation of the results eventually indicate 59 
the need to use alternative in vitro methods for taste evaluations. 
[4,7]
 In the last few years, 60 
electronic tongues (e-tongues) became popular for the evaluation of the in vitro taste 61 
performance for repeatable analysis of pharmaceutical products. 
[12, 13]
  Electronic tongues are 62 
sensor array systems which are able to determine single substances as well as complex 63 
mixtures of various substances. Electronic -tongue is a device simulating human sense of 64 
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taste that allows for the identification and classification of liquid samples. Regardless of the 65 
selected chemical compounds e-tongues work to the recognition of general sample properties 66 
such as specific taste (e.g bitter).  They consist of an array of chemical sensors and a pattern 67 
recognition system. 
[14-16]
 Over the last few years electronic tongue systems have taken the 68 
advantage of different measuring principles including potentiommetry, voltammetry and  69 
amperometry. Currently, there are commercially available e-tongues which have successfully 70 
been employed for taste assessments in various pharmaceutical formulations. Astree e-tongue 71 
(Alpha MOS, France) and taste sensing system TS-5000Z (INSENT, Japan) are two common 72 
e-tongues which have been used as in vitro taste assessment tools
. [17-21] 
73 
The aim of this novel study is the evaluations of the taste masking efficiency of hot 74 
melt extruded formulations of bitter API (PRP) by using two different e-tongues (Astree e-75 
tongue and TS-5000Z) simultaneously and studying the mechanism of the effective taste 76 
masking via extrusion processing. 77 
Materials and methods 78 
Materials 79 
Propranolol HCl (PRP) was purchased from Sigma Aldrich (London, UK). Eudragit L100 80 
(L100) and Eudragit L100-55 (Acryl-EZE) was kindly donated by Evonik Pharma Polymers 81 
(Darmstadt, Germany) and Colorcon ltd respectively. The HPLC solvents were of analytical 82 
grade and purchased from Fisher Chemicals (UK). All materials were used as received. 83 
Preparation of formulation blends and hot-melt extrusion (HME) processing 84 
PRP formulations with L100 and Acryl-EZE to be extruded were mixed properly in 100g 85 
batches for 10 min each. A Turbula (TF2, Basel) mixer was used to blend the powder 86 
formulations (drug/polymers ratio used were 10:90 w/w). Extrusion of all PRP formulations 87 
were performed using a Randcastle single-screw extruder (RCP 0625, USA) equipped with a 88 
5 mm rod die using 100°C/113°C/155°C/155°C/155°C (Feeder to die) temperature profiles. 89 
The screw speed maintained for all extrusion was 15rpm. The produced extrudates (strands) 90 
was grinded by using a Ball Milling system (8 balls, 1.5 cm diameter) to obtain granules 91 
(<500 µm). Grinding by ball milling was carried out with a rotational speed of 400 rpm for 5 92 
min. 93 
Particle morphology and size distribution 94 
Scanning Electron Microscopy (SEM) was used to study the surface morphology of the 95 
extrudates. Samples were mounted on an aluminum stage using adhesive carbon tape which 96 
was then placed in a low humidity chamber prior to the analysis. Samples were also coated 97 
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with gold–palladium, and microscopy was performed using Cambridge Instruments - S630 98 
(Cambridge, UK) operating at an accelerating voltage of 5 kV. All samples were run singlet. 99 
The particle size distribution of the micronized granules of all formulations was 100 
measured by dry sieving. The method involved stacking of the sieves on top of each other 101 
and then placing the test powder (50 g) on the top sieve. The nest of sieves was subjected to a 102 
standardized period of agitation (20 min) and then the weight of the material retained on each 103 
sieve was accurately determined to give the weigh percentage of powder in each sieve size 104 
range. All samples were run triplicate. 105 
Differential scanning calorimetry (DSC) and Modulated temperature DSC analysis  106 
DSC runs of pure actives, physical mixtures and extrudates were carried out using a Mettler-107 
Toledo 823e (Greifensee, Switzerland) differential scanning calorimeter. Sealed aluminium 108 
pans were used to prepared sample weighing about 2-5 mg of samples (n= 3). Samples were 109 
heated at 10°C/min heating rate from -40 to 220
o
C. At the time of heating, samples were 110 
under nitrogen atmosphere. In addition modulated temperature differential scanning 111 
calorimetry (MTDSC) studies were performed from 25
o
C to 250
o
C with an underlying 112 
heating rate of 1
o
C/min. The pulse height was adjusted to 1-2
o
C with a temperature pulse 113 
width of 15-30 s. 114 
In vivo taste masking evaluation 115 
In vivo taste masking evaluation of pure API, polymers and all active extruded formulations 116 
was performed in accordance to the Code of Ethics of the World Medical Association 117 
(Declaration of Helsinki). 
[19]
 Six (6) healthy volunteers of either sex (age 18–25) were 118 
selected (Male = 3, female = 3) from whom informed consent was first obtained (approved 119 
by the Ethics Committee of the University of Greenwich, Ref: UG09/10.5.5.12). All 120 
volunteers were also trained prior to the experiment. The equivalent of 100 mg of pure PRP 121 
or PRP based extrudates (containing equal amounts of API) were held in the mouth for 60 122 
seconds and then spat out. The selection of samples was random and in between of two 123 
samples analysis mineral water was used to wash each volunteer’s mouth. The bitterness was 124 
recorded immediately according to the bitterness intensity scale from 1 to 5 where 1, 2, 3, 4 125 
and 5 indicate none, threshold, moderate, bitter and strong bitterness.  All samples were 126 
evaluated in triplicate. 127 
In vitro taste masking evaluation: Astree E-Tongue (Alpha MOS) 128 
The assays were better performed on Astree e-tongue system equipped with an Alpha M.O.S. 129 
sensor set #2 (for pharmaceutical analysis) composed of 7 specific sensors (ZZ, AB, BA, BB, 130 
CA, DA, JE) on a 48-positions autosampler using 25 ml beakers. Acquisition times were 131 
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fixed at 120s. 
[19]
 All the data generated on Astree system were treated using 132 
multidimensional statistics on AlphaSoft V12.3 software. Each solution was tested on Astree 133 
e-tongue at least 3 times. 3 replicates were taken into account for the statistical treatment. The 134 
average values of all sensors signals between 100 and 120 s constitute the raw data for later 135 
multivariate statistical data processing. This processing allows to map the data on 2-136 
dimension maps (Principal Components Analysis - PCA, Discriminant Factorial Analysis, 137 
Statistical Quality Control, Partial Least Square, etc).  With Astree e-tongue, PCA was used 138 
to evaluate the differences and similarities between various samples or groups of samples. 139 
The samples are represented in a two-dimensional or three-dimensional space with reference 140 
to the selected components (PC1 and PCn). The components are classified according to the 141 
level of information they produce. Astree sensors were cleaned up with deionised water 142 
between each sample measurement. 143 
Sample preparation for Astree E-Tongue 144 
In vitro taste masking evaluation was carried out with an Astree E-Tongue equipped with 7 145 
different sensor sets. To be as close as panellists taste’s conditions, each drug was diluted for 146 
60s under magnetic stirring in 25 ml of deionised water to reach API concentration 147 
corresponding to a final dose of 100 mg. Then solutions were filtered (as the particles can 148 
damage the ASTREE sensors and thus alter the quality of results) with Buchner funnel fitted 149 
with filter paper at 2.5µm pore size (Table 1). Analysis for each API was done in triplicate. 150 
In vitro taste masking evaluation: TS-5000Z sensing system 151 
The assays were realized on TS-5000Z taste sensing system equipped with a BASIC sensor 152 
set (for pharmaceutical analysis) which are suitable for basic APIs composed of 10 specific 153 
sensors (AAE, CT0, CA0, C00, AE1, AC0, AN0, BT0, GL1 ) on a 48-positions autosampler 154 
using 25 ml beakers. Each measurement cycle was consisted of measuring a reference 155 
solution (Vr) followed by sample solution (Vs) and then the aftertaste (Vr) followed by a 156 
cleaning procedure. The ‘‘aftertaste’’ was measured by determining the change in membrane 157 
potential caused by the adsorption of the analyte to the lipid membrane. Sensor outputs for 158 
both taste (also called relative value (R)) and ‘‘aftertaste’’ were then calculated in relation to 159 
the initially determined sensor response to the reference solution (Vr). 
[1, 22]
 Acquisition times 160 
were fixed at 120s with a BT0 negatively charged sensor. All the data generated on TS-161 
5000Z system were treated using multidimensional statistics. Each solution was tested on TS-162 
5000Z at least 4 times and triplicates were taken into account for the statistical treatment. 163 
Sensors were then cleaned up in references solutions (30 mM KCl + 0.3 mM tartaric acid) 164 
between each sample measurement. The samples were dissolved in 50 mL of 10 mM KCl aq. 165 
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solutions and further diluted to prepare 0.03, 0.1, 0.3, and 1 mM solutions as standards. Then 166 
solutions were filtered with Buchner funnel fitted with filter paper at 2.5µm pore size (n=3). 167 
FTIR spectroscopy 168 
FT-IR analysis was performed on the drug, polymer, drug/polymer physical mixtures, and 169 
extrudates using Perkin Elmer PE1600 (Massachusetts 02451 170 
USA) Fourier Transform Infrared Spectra according to the KBr disc method from 400 – 3600 171 
wavelength/cm
-1
 range (n=3). 172 
Nuclear magnetic resonance (NMR) studies 173 
NMR spectra were recorded on a Jeol ECA 500 NMR spectrometer, incorporating a 5mm 174 
inverse probe (The 
1
H operating frequency was 500 MHz). 
1
H NMR spectra of the drugs, 175 
polymers and drug/polymer formulations were recorded using the standard Jeol pulse 176 
sequence. All samples were dissolved in CD3OD, degassed and then maintained at 25
o
C 177 
during data acquisition. Samples were referenced with respect to the solvent. The solution 178 
concentration of the drug was 2mg/ml, the polymers were 18 mg/ml, and the drug/polymer 179 
formulation was 20mg/ml (the overall drug content in the formulations was 10%) (n=3).  
1
H 180 
T1 relaxation experiments were recorded for all samples using a standard inverse recovery 181 
experiment. Recovery delays (τ) were investigated between 10 ms and 20 s. The relaxation 182 
delay was set to be >5T1. T1s were calculated from curve fitting and peak intensities which 183 
were obtained from the spectra recorded for different recovery delays. Jeol, curve fitting 184 
software was utilized during this process.  185 
Statistical analysis 186 
All data generated and collected during in vitro taste analysis by both the e-tongue and taste 187 
sensing system TS-5000Z were treated by statistical methods. Results were expressed as raw 188 
data in mV of the sample relative measurement to the reference. Sensor signal results were 189 
evaluated via multivariate data analysis. Multivariate analysis, such as principal component 190 
analysis (PCA), was used to reduce the multidimensional space without losing information. 191 
Using PCA, the most abundant information contained in the original data could be 192 
transformed into the first principal component (PC-1), and the second most abundant 193 
information is transformed into the second component (PC-2). For multivariate data analysis, 194 
raw data were pretreated by mean centring and scaling to unit variance. Data processing, 195 
graphical illustration and statistical interpretation of the results were carried out using Excel 196 
2010 (Microsoft, Redmond, WA, USA). INSENT and Alpha MOS software.  197 
 198 
 199 
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Results and discussion 200 
Hot-melt extrusion process: Particle morphology and size distribution 201 
Extrusion processing of all PRP based formulations was performed at 155
o
C with relatively 202 
lower screw speed of 15 rpm in order to allow homogenous blending of the drug/polymer 203 
binary mixtures. The rationale underlying selecting high processing temperature was due to 204 
the higher Tgs of polymeric carriers used. Various formulation trials were conducted at the 205 
optimization stage ranging a drug loading 10-20% (w/w ratios). But keeping the final dose in 206 
the finished product e.g. tablets in account, 10% (w/w) drug loading was chosen to proceed 207 
with. Preliminary results showed no significant differences in terms of the solid state of the 208 
extrudates and physical performance between the formulation containing 20% PRP and 10% 209 
PRP. Another reason underlying the selection of PRP- a cationic charged substance,  as a 210 
model drug and two different polymers (anionic charged) as carriers, was to possibly 211 
facilitate an intermolecular interactions in order to mask unpleasant taste of the bitter API. 212 
Theoretical miscibility parameter calculations showed that the solubility parameter of PRP 213 
(21.94 MPa
1/
2 ) calculated by Van Krevelen equation is quite close to that of L100 (22.75 214 
MPa
1/
2 ) and Acryl-EZE (21.65 MPa
1/
2). 
[6]
 It has been reported in previous studies that if the 215 
difference of the solubility parameters between drug and polymer is less than 7MPa
1/2
, then 216 
the polymer is likely to be miscible with the API to form an amorphous solid dispersions.
 [6]
 217 
As a result the cationic PRP may interact with the functional groups of the negatively charged 218 
polymers to effectively mask bitter taste of the drug. 219 
SEM was used to examine the surface morphology of the drug and extrudates. The 220 
extrudates containing L100 and Acryl-EZE showed homogenous particles distribution on the 221 
extrudates surface with PRP (Fig. 1) indicating excellent HME processing of the extruded 222 
materials to form solid dispersions. The particle size distribution depicted in Fig. 1 shows 223 
particle sizes lower than 500 µm for most formulations ranging from 40 – 400µm. A small 224 
percentage can be seen at sizes <40µm as the milling process was optimized to reduce fines 225 
in the final extruded batches.   226 
Solid state analysis 227 
DSC was conducted in order to analyze the solid state (crystalline or amorphous) of the pure 228 
drug, polymers, drug/polymers binary mixtures and drug/polymer extrudates. The thermal 229 
transition of PRP in Fig. 2 showed an endothermic peak corresponding to its melting point at 230 
166.65
o
C (∆H= -126.25 J/g). The bulk polymers showed Tgs at 83.97
o
C and 164.83
o
C 231 
corresponding to Acryl-EZE and L100, respectively (Fig. 2). A sharp melting peak was also 232 
observed in the Acryl-EZE thermogram at 59.2
o
C (data not shown), corresponds to the 233 
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presence of crystalline plasticizers in the co-processed formulation.
[19]
 MTDSC analysis of 234 
the binary physical blends of PRP/L100 and PRP/Acryl-EZE exhibited PRP endothermic 235 
peaks shifted at slightly lower temperatures of 162.41
o
C to 153.62
o
C indicating a 236 
drug/polymer interaction at small extent. The same shift at lower temperatures was also 237 
observed for the Tgs of the polymers at 73.16
o
C and 98.82
 o
C for PRP/Acryl- EZE and 238 
PRP/L100, respectively. 239 
Furthermore, the extruded PRP/Acryl-EZE (and L100) extrudates exhibited single 240 
glass transition peaks at 63.36 and 74.84
o
C, respectively which indicates the presence of 241 
drug/polymers miscibility and formation of molecular solid dispersions. When the two 242 
components are miscible the Tg of the extruded sample lies between the Tgs of the individual 243 
components (amorphous drug and polymers) according to Gordon – Taylor equation. 
[6, 19]
 244 
The Tg of PRP was determined at 34.74
o
C (data not shown). DSC analysis confirmed the 245 
presence of molecular dispersions in all extruded formulations. 246 
Previous studies 
[6]
 showed that the diffraction patterns of both PRP physical mixtures 247 
exhibited crystalline peaks with reduced intensities corresponding to pure drug. The 248 
diffractograms of the extruded formulations were characterized with the absence of drug 249 
intensity peaks indicating amorphous or molecularly dispersed state.  250 
In vivo taste masking  251 
The masking efficiency of the developed granules was evaluated in vivo (approved by 252 
University of Greenwich, UK ethics committee) with the assistance of six healthy human 253 
volunteers (age 18 – 25). The statistical data collected from the in vivo study for the pure 254 
active substance and the extruded formulations are depicted in Fig. 1. The data analysis 255 
showed significant suppression (p< 0.05) of the bitter taste for the API. These results 256 
demonstrate the influence of the polymeric carriers and importance of drug loading in the 257 
final formulation. Both polymers showed effective taste masking capacity with descending 258 
order L100> Acryl-EZE.  Furthermore, the HME formulations presented excellent masking 259 
effect for active concentrations (10%) of the API. This could be due to the possible drug 260 
polymer interactions in the solid dispersions manufactured during extrusion process. In the 261 
solid dispersions cationic active substance (PRP) may have interacted with the functional 262 
group of the negatively charged polymers. These interactions facilitated a hydrogen bonding 263 
interaction between the active amide group of API and carboxylic group of polymers and 264 
consequently masked the bitter taste of the active. A similar study has also been reported 265 
elsewhere. 
[2]
  In Fig. 3 the sensory data obtained from the panelists interestingly showed that 266 
the taste masking efficiency of L100 is not similar to that of Acryl-EZE for the API used. 267 
This could be attributed to the pH dependant dissolution properties of Acryl-EZE (pH ≥ 5.5) 268 
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compared to that of L100 (pH ≥ 6) as the saliva represents a basic pH (~7.4) in healthy 269 
individuals. However, the sensory scores of the API in different formulations are within the 270 
range (below 2) which has been demonstrated as optimum by in vitro evaluations. 
[1, 11]
 271 
In vitro taste evaluations (Astree e-tongue) 272 
Astree e-tongue was used for in vitro taste analysis of the drug and active formulations.  273 
Principal Component Analysis (PCA) associated to complementary data processing was used. 274 
[20]
 Based on the statistical analysis taste maps were constructed in order to determine the 275 
distances between active and polymer solutions. Actually the distance between each active 276 
formulation and its corresponding placebo is indicative of how close or how far the taste of 277 
the two samples is. The interpretation of the taste maps suggests that the shorter the distance 278 
(Euclidean distance) between active and placebo (polymer), the better the taste masking of 279 
the active ingredient. Thus the distance between any drug polymer pairs in the taste maps is 280 
indicative of the taste masking efficiency of the extruded polymer formulations from which 281 
the estimated Discrimination Index (DI in %) can be determined for each solution. This 282 
indicator (DI) takes into account the average difference between the pairs (i.e drug and active 283 
formulation or polymer and active formulation) to compare the dispersion or taste masking 284 
effect. It is assumed that the higher the DI values (maximum 100%), the longer the distance 285 
between groups and the lower the masking effects.  286 
 In Fig. 4a, the taste map shows significant discrimination between placebo and active 287 
solutions with PRP. Liquid sensors were able to detect the presence of the drug in the 288 
extruded formulations. Considering the pure drug in deionized water the extrudates with 289 
L100 (10% drug loading w/w) shows a better taste improvement compared to that of Acryl-290 
EZE (Fig. 4a). The distance between the placebo and the active formulations indicates the 291 
efficiency of the taste masking of the active by both polymers. The observed distance 292 
proximity between extrudates of PRP and placebo is noticeable (for an example, 19% taste 293 
improvements of PRP with L100). This trend is likely to be linked with a pH influence of 294 
Acryl-EZE in deionized water (pH ~5.5) which leads to a higher separation of placebo from 295 
the active formulations by dissolving faster than L100 (pH > 6.0). From the PCA graphs it 296 
can be seen that the placebo, the API, and the extrudates are discriminated which means 297 
significant taste differences.  298 
Based on the Astree e-tongue experimental results it was also possible to design the 299 
DI graphs for the drug – polymer combinations. In Fig. 4b, it can be seen that the distance 300 
between active and placebo formulations with Acryl-EZE (DI 62%) is higher than that of 301 
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L100 (DI 40%) in the extrudates, indicating better taste masking efficiencies of L100 (19% 302 
taste masking/improvement) than Acryl-EZE polymeric system.  303 
However, this was expected as the use of deionized water was intentionally selected 304 
in order to test the sensitivity of the Astree e-tongue in variations of the drug dissolution 305 
rates.  As mentioned above the polymers dissolve in different pH which results faster drug 306 
release for Acryl-EZE compared to L100.  307 
 Sensory correlated models based on Partial Least Square (PLS) were built to evaluate 308 
the correlation with sensory scores. The correlation model is considered as valid and fits with 309 
panel perception (R²>0.80). But it should be taken with care as all data on sensory tests 310 
(number of panelists, variability on measurement) were not communicated. It’s quite obvious 311 
from the Fig. 4c that the in vitro taste assessment studies carried out with Astree e-tongue 312 
correlated very well with the in vivo panelists data (R
2
 =  0.9892 (Acryl-EZE); 0.9959 313 
(L100)). 314 
  PRP was found to be quite bitter by the panelists (sensory score 5) similar to the 315 
Astree e-tongue evaluation. The impact of Acryl-EZE carrier was negligible as Acryl-EZE 316 
itself was also found not to be bitter (sensory score 1).  Contrary, PRP/L100 formulations 317 
demonstrated improved taste masking even though the bulk polymer showed threshold-318 
moderate bitterness. However, the PLS were in good agreement by complementing the in 319 
vivo study, where the panelists recorded a moderate taste with L100 (and no taste with Acryl-320 
EZE).  321 
A further statistical analysis was performed by considering the standard deviations 322 
(SD) and therefore the relative standard deviations (RSD) of all extruded formulations. The 323 
findings of the standard deviations studies for bulk drugs and the extrudates are summarized 324 
in Table 2. It can be seen that the statistical analysis of SD and RSD for all formulations, 325 
showed positive results towards effective taste masking of bitter PRP. It is accepted that the 326 
scale of interpretation measure is SD < 50: Fair and SD < 30: good, respectively. Based on 327 
this scale of interpretation, the results showed (Table 2) that the calculated mean SD values 328 
for all formulations is ≤ 13 which suggests good taste masking of the API in the extruded 329 
formulations. 330 
 331 
INSENT TS-5000Z sensing system 332 
The in vitro masking effect of the extruded formulations in artificial saliva was also evaluated 333 
by using the INSENT TS-5000Z e–tongue. The distance percentages (%) between active 334 
substances and formulation solutions were estimated in four different time intervals (0.5 min, 335 
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1 min, 10 min and 30 min) as they are indicative of taste masking efficiency of the extruded 336 
formulations.  In addition, the discrimination index (DI, %) was determined for each solution. 337 
Initial trials showed that the BT0 sensor of TS-5000Z system responded to the DPD and PRP 338 
at the each concentration ranging from 0.03, 0.1, 0.3 and 1 mM. Therefore, BT0 sensor can 339 
be useful for detecting bitterness of the API in the concentration ranging from 0.03 to 1 mM. 340 
 In contrast with the Astree e-tongue, in INSENT TS-5000Z system, the lower DI 341 
values the longer the distance in taste responses between the pairs (drug and formulations) 342 
and thus a higher discrimination, which means greater masking effect. The DI (%) values can 343 
help to assess the significance of difference between the formulations.  In Fig. 5a the bitter 344 
taste suppression of PRP in the L100 extrudates is quite significant even after 30 min as the 345 
DI index (%) is only about 60% while after 1 min DI is 40% (DI index (%) close to 0% 346 
indicates no taste). In contrast the PRP/ Acryl-EZE extrudates (Fig. 5b) did not show taste 347 
suppression similar to the L100 polymer but still the DI index (%) estimated by the BT0 348 
sensor around 98% after 30 min and 85% in 1 min, respectively was considered effective (but 349 
less than L100).  350 
 The normalized taste graphs showed significant discrimination between all active 351 
formulations and active ingredient solutions (Fig. 5a-b) suggesting lower taste masking 352 
efficiency of Acryl-EZE for the API compared to the taste suppression of L100.   353 
As mentioned before, liquid sensors are able to detect the taste of the drug in the 354 
masked formulations (up to 0.3mM API), therefore the in vitro taste masking results detected 355 
by the BT0 sensor are quite sensitive and consistent. For that reason, in comparison with the 356 
pure drug in the reference solutions (artificial saliva) the extrudates exhibited taste masking 357 
effects. As mentioned above this could be attributed to the pH dependency of both polymers 358 
which present different drug release due to their different pH values. However the e-tongue 359 
sensor did perceive the taste of bitter APIs from the dissolved polymer matrices.   360 
Sensory correlated models were built to evaluate the correlation with sensory scores. 361 
The correlation model was considered as valid and fitted with panel perception (Fig 5c) and 362 
complemented the sensory findings from the panelists’ scores to conclude the statement that 363 
L100 has better taste masking efficiency than Acryl-EZE. The TS-5000Z taste sensing 364 
system demonstrated different sensitivity to each sample with high correlation (R
2
=0.94) to 365 
the taste scores, suggesting that the sensor responds selectively according to bitterness 366 
intensity by providing quantitative information. 367 
The BT0 sensor was also used to determine the taste of pure polymers. Interestingly 368 
as shown in Fig. 5d it was not possible to detect any taste for both L100 and Acryl-EZE. 369 
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Apparently the contribution of the bulk polymers was not taken in account as INSENT uses a 370 
different approach compared to that of Astree e-tongue. 371 
 372 
Fourier Transform Infra-Red (FT-IR) analysis 373 
FT-IR has been used to study interactions in drug/polymer dispersions by providing valuable 374 
information regarding the oppositely charged ionic drug/polymer interactions at molecular 375 
level. 
[23]
 By showing the appearance of additional bands, alterations in wavenumber position 376 
or broadening of functional groups compared to the spectra of the pure drug and polymer the 377 
FTIR spectra gives an indication of drug/polymer interactions. The FTIR spectra for the 378 
extruded formulations are shown in Fig.6.  379 
The characteristic bands of CO- vibrations of the carboxylic acid groups in L100 and 380 
Acryl-EZE are shown at ~1705 cm
-1 
and of the esterified carboxylic groups at ~1735 cm
-1
. 381 
The FTIR spectra of the PRP extrudates in comparison with the pure materials are depicted in 382 
Fig. 6, which showed a new absorption band at ~1560 and ~1555 cm
-1 
for PRP/ L100 and 383 
PRP/ Acryl-EZE, respectively. This is considered to be the result of the presence of amine 384 
group alongside the carboxyl group in the solid dispersions. 
[24]
 During the FTIR process the 385 
resonance is possible between the two CO-bands within COO- groups. As a result, the 386 
characteristic CO- absorption is replaced by the band of auto-symmetrical vibrations of the 387 
COO- group in the 1555- 1560 cm
-1
 region of the FTIR spectra 
[24, 25]
 which belongs to the 388 
polymer (L100 or Acryl-EZE). This type of spectra changes provides strong evidence of 389 
strong interactions between the anionic methacrylate polymers (-COO) and the cationic PRP 390 
(amine group) by enabling the formation of hydrogen bonds with the amine group of the 391 
drug. 392 
NMR analysis 393 
1
H T1 NMR spectroscopy was employed to monitor the possible chemical changes at the 394 
molecular level by analyzing chemical shifts of NMR signals. Such a change has been 395 
observed in regards with the chemical shifts in the 
1
H NMR spectra of drug and drug/polymer 396 
solutions. 
[26, 27] 
Previous studies showed that NMR analysis carried in DMSO successfully 397 
revealed possible drug/polymer interactions in molecular level. Initially solid state NMR was 398 
conducted in order to elucidate possible drug/polymer interactions; however the low drug 399 
loading in our formulations didn’t accord NMR a meaningful interpretation. 
 
400 
1
H T1 NMR experiments were used to analyse spin relaxation times. Different 401 
relaxation rates of nuclear spins can be related to aspects of molecular structure and 402 
additionally to internal molecular motion. The reasoning behind these experiments was to 403 
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look at potential changes of the drug’s molecular motion, before and after the extrusion. 404 
Indeed, it would be assumed that the free drug (with a low molecular weight) would have 405 
quite a high molecular motion leading to fairly high T1 relaxation delays. After formulation, 406 
any consequence of an interaction between the drug and polymer would result in a decrease 407 
in the amount of molecular motion observed for the drug. It can be seen in Fig. 7 that the T1 408 
relaxation times have significantly been decreased in all PRP/L100 formulations. About 16-409 
20 folds of decrease in the T1 relaxation times have been observed in the extruded 410 
formulations. This significantly indicates that the free drug (with a low molecular weight) had 411 
quite a high molecular motion leading to fairly high T1 relaxation delays (times) while the 412 
extruded formulations showed very low T1 relaxation delay. This was due to the strong 413 
drug/polymer interactions leading to a significant decrease in the relaxation time.   T1 414 
relaxation delays are particularly sensitive to intermediate molecular motions which result in 415 
short T1s. Molecules which have fast or slow molecular motion can have comparable T1s. 
[6]
 416 
This NMR analysis indicates the presence of molecular interaction between the drug 417 
and polymers in solutions, although the type of the interactions cannot be elucidated. In 418 
addition, the presence of such intermolecular interaction can contribute to the possible taste 419 
masking mechanism of all drug/polymer combinations during extrusion.  420 
 421 
Conclusions 422 
In this study the performance of two e-tongues was evaluated for the development of taste 423 
masked PRP formulations processed by hot melt extrusion. The optimized formulations were 424 
also evaluated in vivo by panellists and showed very good masking efficiency.  Both e-425 
tongues confirmed that the extruded formulations of PRP/L100 demonstrated better taste 426 
masking compared to those of PRP/ Acryl-EZE. However, each e-tongue interpreted different 427 
extent of taste masking efficiency. The e-tongues evaluation suggests that results should be 428 
cautiously considered in comparison to panellist’s scores. The NMR and FT-IR analysis 429 
confirmed possible drug/polymer intermolecular interaction which could explain the 430 
mechanism underlying the taste suppression in all extruded formulations. 431 
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Tables 541 
 542 
Table 1: Sample preparation for taste masking analysis 543 
Description Type Drug 
(%) 
Polymer 
(%) 
Drug 
(mg) 
Polymer 
(mg) 
Total 
(mg) 
PRP Active  100 0 100 0 100 
Acryl-EZE  Polymer 0 90 0 900 900 
PRP/ Acryl-EZE Extrudates 10 90 100 900 1000 
L100 Polymer 0 90 0 900 900 
PRP/L100 Extrudates 10 90 100 900 1000 
 544 
 545 
Table 2: Mean standard deviation (SD) and relative standard deviation (RSD) for each 546 
solution for in vitro taste analysis by Astree e-tongue. 547 
PRP dissolution after 60s 
Formulation Mean SD Mean RSD (%) Interpretations 
PRP 8.0 0.7 Good 
PRP/ Acryl-EZE 12.0 0.9 Good 
PRP/L100 10.0 1.4 Good 
Acryl-EZE 13.0 1.1 Good 
L100 8.0 0.8 Good 
AVERAGE 13.0 0.7 Good 
 548 
 549 
 550 
 551 
 552 
 553 
 554 
 555 
 556 
 557 
 558 
 559 
 560 
100x
SD
RSD
χ
=
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Figures Caption List 561 
 562 
Fig. 1 SEM images of PRP/polymer extrudates and particle size distribution. 
Fig. 2 DSC thermal transitions of (i) PRP and polymers pure, (ii) PRP/polymer 
extruded formulations. 
Fig. 3 Sensory scores of all formulations by panelist (n=6). 
Fig. 4a Signal comparison between active and placebo formulations with L100 and 
Acryl-EZE and PRP (dissolution for 60s). 
Fig. 4b Distance and discrimination comparison between signal of PRP pure and 
their formulations on Astree e-tongue (after 60s dissolution). 
Fig. 4c Sensory correlation model based on PLS with Astree e-tongue 
Fig. 5a Normalised DI (%) of all drug/L100 formulations in four different time 
scale. 
Fig. 5b Normalised DI (%) of all drug/ Acryl-EZE formulations in four different 
time scale. 
Fig. 5c Relationship between results of taste sensors and human taste scores for 
similar tastes. The standard deviations on the x- and y-axes are the 
difference between the panelists’ scores and measurement error (n = 6), 
respectively. 
Fig. 5d Sensor output of the two polymers, Acryl-EZE and L100. Maximum 
concentrations of polymers were set at 60 times the maximum API conc. 
(approx. 0.5 mg/mL x 60 = 30 mg/mL). 
Fig. 6 FT-IR spectra of PRP extruded formulations. 
Fig. 7 Part, 
1
H T1 spectra (aromatic region) for the PRP pure and taste masked 
formulations. 
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